SILVER SPRING
National Priority Voucher awarded for Zenocutuzumab
- Sponsor
- Partner Therapeutics, Inc.
- Drug
- Bizengri · zenocutuzumab
- Indication
- NRG1 fusion-positive cholangiocarcinoma
FDA awarded a Commissioner’s National Priority Voucher to Partner Therapeutics for Zenocutuzumab in NRG1 fusion-positive cholangiocarcinoma.
What this means
Bizengri (zenocutuzumab) is a targeted antibody treatment that blocks two proteins, HER2 and HER3, which drive certain cancers. The FDA awarded a National Priority Voucher to Partner Therapeutics for its use in NRG1 fusion-positive bile duct cancer. This voucher could speed up future drug reviews and highlights the need for treatments in this rare cancer type.
Drug Watch — recent news on Bizengri
- Arndt Vogel: Zenocutuzumab in Rare NRG1 Fusion-Positive Cholangiocarcinoma - Oncodaily
- Zenocutuzumab Shows Durable Antitumor Activity in NRG1 -Positive Cholangiocarcinoma - The ASCO Post
- Dr Bekaii-Saab on the FDA Approval of Zenocutuzumab in NRG1+ Cholangiocarcinoma - OncLive
- Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO) - PR Newswire
- Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO) - AOL.com